REthinking Clinical Trials



  • Bradbury M, Savard MF, Vandermeer L, Clemons L, Pond G, Hilton JF, Clemons M, McGee S. Shorter durations of anti-HER2 therapy for patients with early-stage, HER2-positive breast cancer: the physician perspective. Curr Oncol, 2023. Dec 14;30(12):10477-10487. doi: 10.3390/curroncol30120763 PMID:38132397 
  • El Kababji S, Mitsakakis N, Fang X, Beltran-Bless AA, Pond G, Vandermeer L, Radhakrishnan D, Mosquera L, Paterson A, Shepherd L, Chen B, Barlow WE, Gralow J, Savard MF, Clemons M, El Emam K. Evaluating the Utility and Privacy of Synthetic Breast Cancer Clinical Trial Data Sets. JCO Clin Cancer Inform. 2023 Sep;7:e2300116. doi: 10.1200/CCI.23.00116. PMID:38011617
  • Fernandes R, Ng TL, Alzahrani MJ, Raphael J, Blanchette P, Black M, Stober C, Pond GR, Cella D, Vandermeer L, Ibrahim M, Clemons M; REaCT Investigators. A Multi-Centre Randomized Study Comparing Two Standard of Care Chemotherapy Regimens for Lower-Risk HER2-Positive Breast Cancer. Curr Oncol. 2023 Aug 4;30(8):7384-7397. doi: 10.3390/curroncol30080535. PMID:37623016
  • Alqahtani N, Clemons M, Vandermeer L, Daigle K. Telephone completion of patient self-reporting health history documents by registered nurses: a survey to evaluate its effectiveness and strategies for improvement. Support Care Cancer. 2023 Aug 19;31(9):529. doi: 10.1007/s00520-023-07980-4. PMID: 37597016
  • Shah H, Wolfe D, Clemons M, Liu M, Thavorn K, Veroniki AA, Lunny C, Pond G, McGee S, Skidmore B, Arnaout A, Hutton B. Can routinely collected administrative data effectively be used to evaluate and validate endpoints used in breast cancer clinical trials? Protocol for a scoping review of the literature. Syst Rev. 2023 Jul 8;12(1):117. doi: 10.1186/s13643-023-02283-5. PMID: 37422656
  • Beltran-Bless AA, Alshamsan B, Alzahrani MJ, Hilton J, Baines K, Samuel V, Pond GR, Vandermeer L, Clemons M, Larocque G. Regularly scheduled physical examinations and the detection of breast cancer recurrences. Breast. 2023 Jun:69:274-280. doi: 10.1016/j.breast.2023.03.004. Epub 2023 Mar 8.2023. PMID: 36922304
  • Fallah P, Wolfe D, Hutton B, Clemons M, Shorr R, Vandermeer L, Rushton M. Management of genitourinary symptoms in patients with breast cancer: an updated systematic review of available evidence from randomized trials. Support Care Cancer. 2023 Jan 25;31(2):131. doi: 10.1007/s00520-023-07583-z. PMID: 36695978
  • Beltran-Bless AA, Clemons M, Fesl C, Greil R, Pond GR, Balic M, Vandermeer L, Bjelic-Radisic V, Singer CF, Steger GG, Helfgott R, Egle D, Sölkner L, Gampenrieder SP, Kacerovsky-Strobl S, Suppan C, Ritter M, Rinnerthaler G, Pfeiler G, Fohler H, Hlauschek D, Hilton J, Gnant M. Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12. Eur J Cancer. 2023 Feb:180:108-116. doi: 10.1016/j.ejca.2022.12.003. Epub 2022 Dec 10. PMID: 36592505
  • Cole KM, Hutton B, Hamel C, Bourque JM, Arnaout A, Clemons M. Breast cancer in Indigenous women living in Canada: a scoping review protocol. JBI Evid Synth. 2021 Jun 23. doi: 10.11124/JBIES-20-00522. PMID:34171894


  • Alshamsan B, Hutton B, Liu M, Vandermeer L, Clemons M. Integrating Systematic Reviews into Supportive Care Trial Design: The Rethinking Clinical Trials (REaCT) Program. Curr. Oncol. 2022, 29, 9550–9559. ttps:// PMID: 36547164
  • Shah H, Vandermeer L, MacDonald F, Larocque G, Nelson S, Clemons M, and McGee S. Delivery of cancer care via an outpatient telephone support line: a cross sectional study of oncology nursing perspectives on quality and challenges. Support Care Cancer 2022 Nov;30(11):9079-9091. doi: 10.1007/s00520-022-07327-5. Epub 2022 Aug 18. PMID: 35980464
  • McGee SF, Clemons M, Savard MF, Evolving Role of Risk Tailored Therapy in Early Stage HER2-Positive Breast Cancer: A Canadian Perspective. Curr Oncol. 2022 Jun 6;29(6):4125-4137. doi: 10.3390/curroncol29060329.PMID: 35735438
  • Cole KM, Clemons M, McGee S, Alzahrani M, Larocque G, MacDonald F, Liu M, Pond G, Mosquera L, Vandermeer L, Hutton B, Piper A, Fernandes R, El Emam K. Using machine learning to predict individual patient toxicities from cancer treatments. Support Care Cancer. 2022 May; 30 (5) :4437-4446. doi: 10.1007/s00520-022-06848-3. PMID: 35614153
  • Cole KM, Clemons M, Alzahrani M, Liu M, Laroque G, MacDonald F, Hutton B, Piper A, Fernandes R, Pond G, Vandermeer L, El Emam K, McGee S. Vasomotor symptoms in early breast cancer—a “real world” exploration of the patient experience. Support Care Cancer. 2022 doi: 10.1007/s00520-022-06848-3. PMID: 35112212
  • Alzahrani M, Clemons M, Chang L, Vandermeer L, Arnaout A, Larocque G, Cole K, Hsu T, Saunders D, Savard M.-F. Management strategies for older patients with low risk early stage breast cancer: a physician survey. Curr. Oncol. 2022. 29, 1–13. PMID: 35049675
  • Alzahrani M, Stober C, Liu M, Awan A A, Ng T L, Pond G, Alshamsan B, Vandermeer L, Clemons M. Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers. Support Care Cancer. 2022 Jan 21. doi: 10.1007/s00520-021-06714-8. PMID: 35059864


  • Savard MF, Alzahrani M J, Saunders D, Chang L, Arnaout A, Ng, T L, Brackstone M, Vandermeer L, Hsu T, Awan A A, Cole K, Larocque G, Clemons M. Experiences and Perceptions of Older Adults with Lower-risk Hormone Receptor-positive Breast Cancer about Adjuvant Radiotherapy and Endocrine Therapy: A Patient Survey. Curr Oncol. 2021 Dec 8;28(6):5215-5226. doi: 10.3390/curroncol28060436. PMID: 34940075
  • Dent S, Fergusson D, Aseyev O, Stober C, Pond GR, Awan AA, McGee SF, Ng T, Simos D, Vandermeer L, Saunders D, Hilton JF, Hutton B, Clemons M. A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer. Curr Oncol. 2021 Dec 3;28(6):5073-5083. doi: 10.3390/curroncol28060427. PMID: 34940066
  • Awan A, Basulaiman B, Stober C, Clemons M, Fergusson D, Hilton J, Al Ghareeb W, Goodwin R, Ibrahim M, Hutton B, Vandermeer L, Mallick R, Vickers M. A comparison of oral magnesium supplements for cancer treatment-induced hypomagnesemia: results from a pilot randomized trial. Health Science Reports. 2021 PMID: 34938893
  • Saunders D, Liu M, Vandermeer L, Alzahrani MJ, Hutton B, Clemons M. The Rethinking Clinical Trials (REaCT) Program. A Canadian-Led Pragmatic Trials Program: Strategies for Integrating Knowledge Users into Trial Design.  C Oncol. 2021, 28(5), 3959-3977; PMID: 34677255
  • Bradbury M, Hutton B, Beltran-Bless AA, Alzahrani MJ, Lariviere T, Fernandes R, Ibrahim MFK, Cole K, Hilton J, Vandermeer L, Shorr R, Larocque G, Clemons M. Time to update evidence-based guideline recommendations about concurrent tamoxifen and antidepressant use? A systematic review. Clin Breast Cancer. 2021. PMID:
  • Clemons M, Liu M, Stober C, Pond G, Alzahrani MJ, Ong M, Ernst S, Booth C, Mates M, Joy AA, Aseyev O, Blanchette P, Vandermeer L, Tu M, Thavorn K, Fergusson D. Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer. Journal of Bone Oncology. 30, (2021) 100388. PMID: 34567960
  • Savard MF, Clemons M, Hutton B, Alzahrani MJ, Caudrelier JM, Vandermeer L, Liu Michelle, Saunders D, Sienkiewicz M, Stober C, Cole K, Shorr R, Arnaout A, Chang L. De-escalating adjuvant therapies in older patients with lower risk estrogen receptor-positive breast cancer treated with breast-conserving surgery: A systematic review and meta-analysis. Cancer Treatment Reviews, 99 (2021) 102254. PMID: 34242928
  • Beltran-Bless A, Vandermeer L, Ibrahim M.F.K., Hutton B, Shorr R, Savard MF, Clemons M. Does the Time of Day at Which Endocrine Therapy Is Taken Affect Breast Cancer Patient Outcomes?. Current Oncology. 2021, 28, 2523–2528. PMID: 34287262
  • Alzahrani MJ, Dranitsaris G, Sienkiewicz M, Vandermeer L, Clemons M. Clinical utility of a prediction tool to differentiate between breast cancer patients at high or low risk of chemotherapy-induced nausea and vomiting. Support Care Cancer. 2021 Jun 26. doi: 10.1007/s00520-021-06358-8. Online ahead of print. PMID: 34176018
  • Tu et al, Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer. Current Oncology. 2021, 28(3), 1847 – 1856; doi: 10.3390/curroncol28030171. PMID: 34068083
  • Clemons M, Fergusson D, Joy AA, Meza-Junco J, Price Hiller J, Mackey J, Ng T, Zhu X, Ibrahim MFK, Sienkiewicz M, Saunders D, Vandermeer L, Pond G, Basulaiman B, Awan A, Pitre L, Nixon NA, Hutton B, Hilton J. A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia. Breast. 2021 Aug;58:42-49. doi: 10.1016/j.breast.2021.03.012. Epub 2021 Apr 1. PMID: 33901921
  • Surujballi J, Shah H, Hutton B, Alzahrani M, Beltran-Bless A, Shorr R, Larocque G, McGee S, Cole K, Ibrahim MFK, Fernandes R, Arnaout A, Stober C, Liu M, Sienkiewicz M, Saunders D, Vandermeer L, Clemons M. Practicing during COVID-19: A systematic review evaluating the frequency of follow-up visits for patients with early stage breast cancer. Cancer Treat Rev. 2021 Jun;97:102188. doi: 10.1016/j.ctrv.2021.102188. Epub 2021 Mar 23. PMID: 33813329
  • Alzahrani M, Clemons M, Sienkiewicz M, Shrem NS, McGee SF, Vandermeer L, Sehdev S, Savard MF, Awan A, Canil C, Hutton B, Pond G, Saunders D, Ng TL. Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: A patient survey.  Support Care Cancer. 2021 May 22;1-10.  doi: 10.1007/s00520-021-06238-1. PMID: 34023950
  • Cole KM, Clemons M, AlZahrani M, Larocque G, MacDonald F, Vandermeer L, Hutton B, Piper A, Pond G, McGee S. Developing Patient-Centered Strategies to Optimize the Management of Vasomotor Symptoms in Breast Cancer Patients: A Survey of Health Care Providers. Breast Cancer Res Treat. 2021 Jun 22;1-8.  doi: 10.1007/s10549-021-06186-8.  PMID: 34159473
  • Clemons, M, Simos, D, Sienkiewicz, M, Ng T, Zibdawi L, Basulaiman B, Awan A, Fergusson D, Vandermeer L, Saunders D, Hutton B, Amir E, A Prospective Multi-Centre, Randomized Study Comparing the Addition of Tapering Dexamethasone to other Standard of Care Therapies for Taxane-Associated Pain Syndrome (TAPS) in breast cancer patients.  Support Care Cancer. 2021 Mar 19.  doi: 10.1007/s00520-021-06142-8. PMID: 33742240
  • McGee A, AlZahrani M, Vandermeer L, Cole K, Larocque G, Awan A, Hutton B, Pond G, Saunders D, and Clemons M. Adjuvant bisphosphonate use in patients with early stage breast cancer: A physician surv Breast Cancer Res Treat. 2021 Jun;187(2):477-486. doi: 10.1007/s10549-021-06147-1. Epub 2021 Mar 23. PMID: 33755864
  • McGee A, AlZahrani M, Stober C, Ng TL, Cole K, Larocque G, Awan A, Sehdev A, Hilton J, Vandermeer L, Hutton B, Pond G, Saunders D, Clemons M.  Adjuvant bisphosphonate use in patients with early stage breast cancer: Patient perspectives on treatment acceptability and potential de-escalationJ Bone Oncol. 2021 Feb 19;27:100351doi: 10.1016/j.jbo.2021.100351. eCollection 2021 Apr. PMID: 33680749 
  • Awan A, Ng TL, Conter H, Raskin W, Stober C, Simos D, Pond G, Dhesy-Thind S, Mates M, Kumar V, Fergusson D, Hutton B, Saunders D, Vandermeer L, Clemons M. Feasibility outcomes of a randomised, multicentre, pilot trial comparing standard 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early stage breast cancer.  J Bone Oncology. 2020 Dec 13; 26: 100343.  doi: 10.1016/j.jbo.2020.100343. eCollection 2021 Feb. PMID: 33425673 


  • Arnaout A, Zhang J, Frank S, Momtaz M, Cordeiro E, Roberts R, Ghumman A, Fergusson D, Stober C, Pond G, Jeong A, Vandermeer L, Hutton B, Clemons M. A randomised controlled trial comparing Alloderm-RTU with DermACELL in immediate subpectoral implant-based breast reconstruction.  Curr. Oncol. 202128(1), 184-195. A Randomized Controlled Trial Comparing Alloderm-RTU with DermACELL in Immediate Subpectoral Implant-Based Breast Reconstruction. 
  • AlZahrani M, Clemons M, Vandermeer L, Sienkiewicz M, Awan AA, Hutton B, Pond Greg, Ng TL.  Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey.  Journal of Bone Oncology. 2021 Feb: 26: Online ahead of print. PMID: 33294318
  • Clemons M, Dranitsaris G, Sienkiewicz M, Sehdev S, Ng T, Robinson A, Mates M, Hsu T, McGee S, Freedman O, Kumar V, Fergusson D, Hutton B, Vandermeer L, Hilton J. A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting. Breast. 2020 Nov 10;54:278-285. doi: 10.1016/j.breast.2020.11.002. Online ahead of print. PMID: 33242754
  • Shah H, Surujballi J, Awan AA, Hutton B, Arnaout A, Shorr R, Vandermeer L, Alzahrani MJ, Clemons M. A scoping review characterizing “Choosing Wisely®” recommendations for breast cancer management. Breast Cancer Res Treat. 2020 Nov 6. doi: 10.1007/s10549-020-06009-2. Online ahead of print. PMID: 33156490
  • Hsu T, Fergusson D, Stober C, Daigle K, Moledina N, Vandermeer L, Pond G, Hilton J, Hutton B, M Clemons. A randomised clinical trial comparing physician-directed or fixed-dose steroid replacement strategies for incomplete dexamethasone dosing prior to docetaxel chemotherapy. Support Care Cancer. 2020 Oct 15. doi: 10.1007/s00520-020-05791-5. Online ahead of print.  PMID: 33057999
  • Clemons M, Ong M, Stober, C, Ernst S, Booth C, Canil C, Mates M, Roberson A, Blanchette P, Joy AA, Hilton J, Aseyev O, Pond G, Jeong A, Hutton B, Mazzarello S, Vandermeer L, Kushnir I, Fergusson D. A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer. Eur J Cancer. 2020 Oct 3. S0959-8049(20)30470-6. doi: 1016/j.ejca.2020.08.019. PMID: 33023785
  • Hutton B, Hersi M, Cheng W, Pratt M, Barbeau P, Mazzarello S, Ahmadzai N, Skidmore B, Morgan SC, Bordeleau L, Ginex PK, Sadeghirad B, Morgan RL, Cole KM, Clemons M. Comparing Interventions for Management of Hot Flashes in Patients With Breast and Prostate Cancer: A Systematic Review With Meta-Analyses. Oncol Nurs Forum. 2020 Jul 1;47(4):E86-E106. doi: 10.1188/20.ONF.E86-E106. PMID: 32555553
  • Apte SS, Moloo H, Jeong A, Liu M, Vandemeer L, Suh K, Thavorn K, Fergusson DA, Clemons M, Auer RC. Prospective randomised controlled trial using the REthinking Clinical Trials (REaCT) platform and National Surgical Quality Improvement Program (NSQIP) to compare no preparation versus preoperative oral antibiotics alone for surgical site infection rates in elective colon surgery: a protocol. BMJ Open. 2020 Jul 9;10(7):e036866. doi: 10.1136/bmjopen-2020-036866. PMID: 32647023
  • Ng TL, Tu MM, Ibrahim MFK, Basulaiman B, McGee SF, Srikanthan A, Fernandes R, Vandermeer L, Stober C, Sienkiewicz M, Jeong A, Saunders D, Awan AA, Hutton B, Clemons MJ. Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review. Support Care Cancer. 2020 Jun 13. doi: 10.1007/s00520-020-05556-0. Online ahead of print. PMID: 32535678
  • Clemons M, Fergusson D, Simos D, Mates M, Robinson A, Califaretti N, Zibdawi L, Bahl M, Raphael J, Ibrahim MFK, Fernandes R, Pitre L, Aseyev O, Stober C, Vandermeer L, Saunders D, Hutton B, Mallick R, Awan AA, Hilton J. A multi-centre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer.  Ann Oncol 2020 Apr 20; S0923-7534(20)39296-6. doi: 10.1016/j.annonc.2020.04.005.
  • Robertson SJ, Pond GR, Hilton J, Petkiewicz SL, Ayroud Y, Kos Z, Gravel DH, Stober C, Vandermeer L, Arnaout A, Clemons M. Selecting Patients for Oncotype DX Testing Using Standard Clinicopathologic Information. Clin Breast Cancer. 2020 Feb;20(1):61-67. doi: 10.1016/j.clbc.2019.07.006. Epub 2019 Aug 22. PMID: 31551182
  • Clemons M, Stober C, Kehoe A, Bedard D, MacDonald F, Brunet MC, Saunders D, Vandermeer L, Mazzarello S, Awan A, Basulaiman B, Robinson A, Mallick R, Hutton B, Fergusson D. A randomized trial comparing vascular strategies for patients receiving chemotherapy trastuzumab for early-stage breast cancer.  Support Care Cancer. 2020 Jan 30. doi: 10.1007/s00520-020-05326-y. [Epub ahead of print] PMID: 32002617


  • Robinson A, Stober C, Fergusson D, Kehoe A, Bedard D, MacDonald F, Brunet MC, Saunders D, Mazzarello S, Vandermeer L, Joy AA, Awan A, Basulaiman B, Mallick R, Hutton B, Clemons M; REaCT investigators. A multicentre, randomized pilot trial comparing vascular access strategies for early stage breast cancer patients receiving non-trastuzumab containing chemotherapy. Breast Cancer Res Treat. 2019 Nov;178(2):337-345. doi: 10.1007/s10549-019-05388-5. Epub 2019 Aug 7.  PMID: 31392518
  • de Lima MAG, Clemons M, Van Katwyk S, Stober C, Robertson SJ, Vandermeer L, Fergusson D, Thavorn K. Cost analysis of using Magee scores as a surrogate of Oncotype DX for adjuvant treatment decisions in women with early breast cancer. J Eval Clin Pract. 2019 Jul 9. doi: 10.1111/jep.13223. [Epub ahead of print]. PMID: 31287198
  • Clemons M, Ong M, Stober, C, Ernst S, Booth C, Canil C, Mates M, Roberson A, Blanchette P, Joy AA, Hilton J, Aseyev O, Pond G, Jeong A, Hutton B, Mazzarello S, Vandermeer L, Kushnir I, Fergusson D.  A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer. ASCO 2019 Abstract 11501
  • Awan AA, Hutton B, Hilton J, Mazzarello S, Van Poznak C, Vandermeer L, Bota B, Stober C, Sienkiewicz M, Fergusson D, Shorr R, Clemons M. De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2019 Aug;176(3):507-517. doi: 10.1007/s10549-019-05265-1. Epub 2019 May 11. PMID: 31079283
  • Basulaiman B, Awan AA, Fergusson D, Vandermeer Lisa, Arnaout A, Hilton J, Hutton B, Joy AA, Robinson A, Califaretti N, Stober C, Sienkiewicz M, Thavorn K, Clemons M. Creating a pragmatic trials program for breast cancer patients: Rethinking Clinical Trials (REaCT). BreastCancer Res Treat. 2019 Aug;177(1):93-101. doi: 10.1007/s10549-019-05274-0. Epub 2019 May 24.
  • Robertson SJ, Ibrahim MFK, Stober C, Hilton J, Kos Z, Mazzarello S, Ramsay T, Fergusson D, Vandermeer L, Mallick R, Arnaout A, Dent SF, Segal R, Sehdev S, Gertler S, Hutton B, Clemons M. Does integration of Magee equations into routine clinical practice affect whether oncologists order the Oncotype DX test? A prospective randomized trial. J Eval Clin Pract. 2019 Apr;25(2):196-204. doi: 10.1111/jep.13094. Epub 2019 Jan 23. PMID: 30672056


  • Robinson, A, Souied, O, Bota, AB, Levasseur, N, Stober, N, Hilton, J, Kamel, D, Hutton, B, Vandermeer, L, Mazzarello, S, Joy, AA, Fergusson, D, McDiarmid, S, McInnes, M, Shorr, R, Clemons, M. Optimal vascular access strategies for patients receiving chemotherapy for early-stage breast cancer: a systematic review. Breast Cancer Res Treat. 2018 Oct;171(3):607-620. doi: 10.1007/s10549-018-4868-x. Epub 2018 Jul 4.
  • Fernandes R, Majeed H, Hutton B & Clemons M et al. Optimal type, duration and timing of granulocyte colony stimulating factor (GCSF) for primary febrile neutropenia prophylaxis in patients receiving chemotherapy for early-stage breast cancer – a systematic review. J Glob Oncol. 2018 Sep;4:1-8. doi: 10.1200/JGO.2016.008540. Epub 2017 Apr 21.
  • LeVasseur, N, Stober, C, Daigle, K, Robinson, A, McDiarmid, S, Mazzarello, S Hutton, B, Joy, AA, Fergusson, D, Hilton, J, McInnes, M, Clemons, M. Optimising vascular access for patients receiving intravenous systemic therapy for early-stage breast cancer – A survey of oncology nurses and physicians. Curr Oncol. 2018 Aug;25(4):e298-e304. doi: 10.3747/co.25.3903. Epub 2018 Aug 14.
  • LeVasseur, N, Stober, C, Ibrahim, M, Gertler S, Hilton, J, Robinson, A, McDiarmid, S,Fergusson, D, Mazzarello, S, Hutton, B, Joy, AA, McInnes, M, Clemons, M. Perceptions around vascular access for intravenous systemic therapy and risk factors for lymphedema in early-stage breast cancer – A patient survey. Curr Oncol. 2018 Aug;25(4):e305-e310. doi: 10.3747/co.25.3911. Epub 2018 Aug 14.
  • Hilton J, Vandermeer L, Sienkiewicz M, Mazzarello S, Hutton B, Stober C, Fergusson D, Blanchette P, Joy AA, Brianne Bota A, Clemons M. Filgrastim use in patients receiving chemotherapy for early-stage breast cancer-a survey of physicians and patients. Support Care Cancer. 2018 Feb 6. doi: 10.1007/s00520-018-4074-8. [Epub ahead of print] PubMed PMID: 29411131.


  • Fernandes R, Mazzarello S, Stober C, Vandermeer L, Dudani S, Ibrahim MF, Majeed H, Perdrizet K, Shorr R, Hutton B, Fergusson D, Clemons M. Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review. Breast Cancer Res Treat. 2017 Jan;161(1):1-10. doi: 10.1007/s10549-016-4028-0. Epub 2016 Oct 25. Review. PubMed PMID: 27783280
  • Jacobs C, Clemons M, Mazzarello S, Hutton B, Joy AA, Brackstone M, Freedman O, Vandermeer L, Ibrahim M, Fergusson D, Hilton J. Enhancing accrual to chemotherapy trials for patients with early stage triple-negative breast cancer: a survey of physicians and patients. Support Care Cancer. 2017 Jun;25(6):1881-1886. doi: 10.1007/s00520-017-3580-4. Epub 2017 Jan 27. PubMed PMID: 28127659.
  • Ibrahim MFK, Hilton J, Mazzarello S, Fergusson D, Hutton B, Robinson A, Califaretti N, Hsu T, Gertler S, Mates M, Stober C, Vandermeer L, Mallick R, Clemons M. A multi-center pragmatic, randomized, feasibility trial comparing standard of care schedules of filgrastim administration for primary febrile neutropenia prophylaxis in early-stage breast cancer. Breast Cancer Res Treat. 2017 Dec 6. doi: 10.1007/s10549-017-4604-y. [Epub ahead of print] PubMed PMID: 29214415.


  • Hilton J, Mazzarello S, Fergusson D, Joy AA, Robinson A, Arnaout A, Hutton B, Vandermeer L, Clemons M. Novel Methodology for Comparing Standard-of-Care Interventions in Patients With Cancer. J Oncol Pract. 2016 Dec;12(12):e1016-e1024. Epub 2016 Sep 30. PubMed PMID: 27650842.
  • Fernandes R, Mazzarello S, Hutton B, Shorr R, Ibrahim MF, Jacobs C, Ong M, Clemons M. A Systematic Review of the Incidence and Risk Factors for Taxane Acute Pain Syndrome in Patients Receiving Taxane-Based Chemotherapy for Prostate Cancer. Clin Genitourin Cancer. 2017 Feb;15(1):1-6. doi: 10.1016/j.clgc.2016.07.018. Epub 2016 Jul 28. Review. PubMed PMID: 27554586.
  • Fernandes R, Mazzarello S, Hutton B, Shorr R, Majeed H, Ibrahim MF, Jacobs C, Ong M, Clemons M. Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review. Support Care Cancer. 2016 Aug;24(8):3633-50. doi: 10.1007/s00520-016-3256-5. Epub 2016 May 5. Review. PubMed PMID: 27146496.


  • Hutton B, Mazzarello S, Clemons M. Dosing Strategies of Bone-Targeting Agents. JAMA Intern Med. 2015 Nov;175(11):1864-5. doi: 10.1001/jamainternmed.2015.4789. PubMed PMID: 26524744.
  • Jacobs C, Hutton B, Mazzarello S, Smith S, Joy A, Amir E, Ibrahim MF, Gregario N, Daigle K, Eggert L, Clemons M. Optimisation of steroid prophylaxis schedules in breast cancer patients receiving docetaxel chemotherapy-a survey of health care providers and patients. Support Care Cancer. 2015 Nov;23(11):3269-75. doi: 10.1007/s00520-015-2731-8. Epub 2015 May 3. PubMed PMID: 25933700.
  • Fernandes R, Mazzarello S, Majeed H, Smith S, Shorr R, Hutton B, Ibrahim MF, Jacobs C, Ong M, Clemons M. Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy-a systematic review. Support Care Cancer. 2016 Apr;24(4):1583-94. doi: 10.1007/s00520-015-2941-0. Epub 2015 Sep 19. Review. PubMed PMID: 26386706.
  • Ibrahim MF, Mazzarello S, Shorr R, Vandermeer L, Jacobs C, Hilton J, Hutton B, Clemons M. Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis. Ann Oncol. 2015 Nov;26(11):2205-13. doi: 10.1093/annonc/mdv284. Epub 2015 Jun 28. Review. PubMed PMID: 26122727.


  • Hutton B, Addison CL, Clemons M. The ZOOM trial: more boon than doom? Lancet Oncol. 2013 Sep;14(10):e387-8. doi: 10.1016/S1470-2045(13)70297-3. PubMed PMID: 23993380.
  • Hutton B, Morretto P, Emmenegger U, Mazzarello S, Kuchuk I, Addison CL, Crawley F, Canil C, Malone S, Berry S, Fergusson D, Clemons M. Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: A patient survey. J Bone Oncol. 2013 Jun 21;2(3):105-9. doi: 10.1016/j.jbo.2013.05.002. eCollection 2013 Sep. PubMed PMID: 26909279; PubMed Central PMCID: PMC4723402.
  • Hutton B, Addison C, Mazzarello S, Joy AA, Bouganim N, Fergusson D, Clemons M. De-escalated administration of bone-targeted agents in patients with breast and prostate cancer-A survey of Canadian oncologists. J Bone Oncol. 2013 Apr 15;2(2):77-83. doi: 10.1016/j.jbo.2013.03.001.